Ankylosing Spondylitis/ Ankylosing Spondyloarthritis
Ankylosing Spondylitis study enrolling now at our Schaumburg and Skokie clinics.
For more information or to see if you qualify, please fill out the questionnaire below or call Maria at 847-594-2926.
Spondyloarthritis (SpA) is a group of interrelated chronic inflammatory disease conditions with common clinical features. AS, is characterized by involvement of the bones of the head and trunk of the vertebra and the sacroiliac joints (the spine and pelvis), but also may affect peripheral joints (for example, shoulder) and extra articular organs (for example, heart, lung, skin, bone and kidney). Although the exact reason for occurrence of AS is unknown, several heredities are likely to be involved in susceptibility to the disease. AS causes severe, chronic pain and stiffness in the joints affected, most often the spine and hips. As the condition progresses, it can cause joints in the spine to become fixed or fused, which can lead to a loss of mobility and/or a curved posture.
The study drug ABY-035 investigated in this clinical study is a small therapeutic protein product blocking the pro-inflammatory cytokine IL-17, which is known to play an important role in the development of AS. ABY-035 has demonstrated to have a favorable safety profile and appears efficacious in studies in psoriasis.
We are looking for people who:
- Have active Ankylosing Spodylitis
- Are at least 18 years old
- Have been treated with at least two NSAIDs such as ibuprofen (Advil, Motrin) or naproxen (Aleve) without symptom relief or cannot take these medications due to side effects or safety reason
- May be biologic naive or may have received up to 2 biologics, such as (Enbrel, Humira, Avsola, Simponi Aria etc)
All study related care and investigational medication is at no cost.
Compensation for time and travel is available